ShockWave Medical (SWAV) Scheduled to Post Earnings on Monday

ShockWave Medical (NASDAQ:SWAVGet Rating) will be posting its quarterly earnings results after the market closes on Monday, November 7th. Analysts expect ShockWave Medical to post earnings of $0.68 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

ShockWave Medical (NASDAQ:SWAVGet Rating) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.25. ShockWave Medical had a return on equity of 21.25% and a net margin of 15.11%. The company had revenue of $120.70 million during the quarter, compared to the consensus estimate of $107.51 million. During the same period in the previous year, the company posted ($0.01) earnings per share. ShockWave Medical’s revenue for the quarter was up 115.5% on a year-over-year basis. On average, analysts expect ShockWave Medical to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

ShockWave Medical Trading Down 2.0 %

Shares of NASDAQ:SWAV opened at $274.39 on Friday. ShockWave Medical has a 12-month low of $113.36 and a 12-month high of $320.54. The company has a market capitalization of $9.82 billion, a PE ratio of 187.94 and a beta of 1.03. The business has a 50 day moving average of $280.49 and a two-hundred day moving average of $227.11. The company has a current ratio of 5.32, a quick ratio of 4.41 and a debt-to-equity ratio of 0.02.

Insider Buying and Selling

In related news, VP Trinh Phung sold 3,500 shares of the stock in a transaction dated Friday, August 26th. The stock was sold at an average price of $310.76, for a total transaction of $1,087,660.00. Following the transaction, the vice president now owns 25,063 shares of the company’s stock, valued at approximately $7,788,577.88. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other ShockWave Medical news, VP Trinh Phung sold 3,500 shares of the company’s stock in a transaction dated Friday, August 26th. The stock was sold at an average price of $310.76, for a total transaction of $1,087,660.00. Following the sale, the vice president now owns 25,063 shares in the company, valued at approximately $7,788,577.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Douglas Evan Godshall sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $280.60, for a total value of $8,418,000.00. Following the sale, the chief executive officer now owns 112,926 shares in the company, valued at approximately $31,687,035.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 108,450 shares of company stock valued at $30,990,329. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ShockWave Medical

Large investors have recently bought and sold shares of the stock. PenderFund Capital Management Ltd. purchased a new position in shares of ShockWave Medical in the 1st quarter valued at about $41,000. Canada Pension Plan Investment Board increased its holdings in shares of ShockWave Medical by 36.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 800 shares of the company’s stock valued at $166,000 after acquiring an additional 213 shares during the last quarter. Graham Capital Management L.P. purchased a new position in shares of ShockWave Medical in the 1st quarter valued at about $212,000. Cim Investment Management Inc. purchased a new position in shares of ShockWave Medical in the 1st quarter valued at about $219,000. Finally, Captrust Financial Advisors increased its holdings in shares of ShockWave Medical by 306.8% in the 1st quarter. Captrust Financial Advisors now owns 1,196 shares of the company’s stock valued at $248,000 after acquiring an additional 902 shares during the last quarter. Hedge funds and other institutional investors own 95.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on SWAV shares. Oppenheimer cut ShockWave Medical from a “market perform” rating to an “underperform” rating and set a $165.00 price objective for the company. in a research report on Tuesday, September 6th. Wells Fargo & Company boosted their price target on ShockWave Medical from $176.00 to $255.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 9th. Morgan Stanley boosted their price objective on ShockWave Medical from $255.00 to $290.00 and gave the stock an “equal weight” rating in a research note on Tuesday, October 11th. Piper Sandler boosted their price objective on ShockWave Medical from $278.00 to $338.00 and gave the stock an “overweight” rating in a research note on Monday, August 29th. Finally, Canaccord Genuity Group boosted their price objective on ShockWave Medical from $232.00 to $256.00 and gave the stock a “buy” rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $250.88.

About ShockWave Medical

(Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Featured Articles

Earnings History for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.